<DOC>
	<DOCNO>NCT02998645</DOCNO>
	<brief_summary>This two-part study , interventional Phase II , single-arm , multicenter , open-label study investigate efficacy safety combination regimen eltrombopag cyclosporine patient severe aplastic anemia ( SAA ) first line therapy extension 60-months follow-up . All patient receive eltrombopag 6 month cyclosporine . Patients respond ( overall hematologic response 6 month ) continue taper cyclosporine 30 month follow post-treatment follow-up 60 month regular clinic visit . Patients overall hematologic response ( non-responders ) end 6 month time point discontinue treatment follow non-responder post-treatment follow-up 60 month The usage eltrombopag cyclosporine combine two therapy different mode action . Cyclosporine act immunosuppressant eltrombopag act stimulator bone marrow progenitor cell . Given SAA currently view autoimmune pathogenesis result bone marrow progenitor cell destruction , combination eltrombopag cyclosporine attractive . Preliminary experience combine use appear favorable , untoward toxicity observe date .</brief_summary>
	<brief_title>Eltrombopag Combined With Cyclosporine First Line Therapy Patients With Severe Acquired Aplastic Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>1 . Patient sign Informed Consent ( ICF ) prior screen procedure perform . 2 . Patient male/female ≥6 year old time inform consent able swallow tablet . 3 . Patient SAA characterize : 1 . Bone marrow cellularity &lt; 30 % ( exclude lymphocyte ) 2 . At least two follow ( peripheral blood ) : Absolute neutrophil count &lt; 500/ µL Platelet count &lt; 20,000/ µL Absolute reticulocyte count &lt; 60,000/ µL 4 . Normal ECG define follow determined via mean triplicate ECG Resting heart rate 6 &lt; 12 year : 60130 bpm 12 &lt; 18 year : 60120 bpm ≥18 year : 5090 bpm QTcF screen &lt; 450 msec ( male patient ) , 460 msec ( female patient ) 1 . Diagnosis Fanconi anemia . 2 . Evidence clonal hematologic bone marrow disorder cytogenetics . Patients severe neutropenia ( ANC &lt; 200 /μL ) exclude initially cytogenetics available pending . If clonal disorder identify , patient exclude . 3 . Prior immunosuppressive therapy cyclosporine , alemtuzumab , rabbit horse ATG thrombopoietin receptor ( TPOR ) agonists . 4 . Hypersensitivity eltrombopag component . 5 . AST ALT &gt; 3 x ULN . 6 . Creatinine , total bilirubin , alkaline phosphatase &gt; 3 x ULN . 7 . Patient liver cirrhosis . 8 . Infection adequately control appropriate therapy . 9 . Moribund status concurrent hepatic , renal , cardiac , neurologic , pulmonary , infectious , metabolic disease severity would preclude patient 's ability consent , compliant study procedure , tolerate protocol therapy , death within 30 day likely . 10 . Patients cancer consider cure , active chemotherapeutic treatment take drug hematological effect . 11 . Administration investigational drug within 30 day 5 halflives , whichever longer , precede first dose study treatment . 12 . Pregnancy statement contraception requirement : Pregnancy nursing ( lactate ) woman Women childbearing potential , defined woman physiologically capable become pregnant ( female partner male patient ) , unless use highly effective method contraception dose 3 month stop medication . 13 . Not able understand investigation nature study give inform consent . 14 . Clinically significant ECG abnormality include cardiac arrhythmia ( e. g. ventricular tachycardia ) complete leave bundle branch block , high grade atrioventricular block , inability determine QTcF interval ECG . 15 . Presence cardiac disease , family history idiopathic sudden death congenital long QT syndrome . 16 . Risk factor Torsades de Pointe include uncorrected hypokalemia hypomagnesemia , use concomitant medication ( ) know risk prolong QT interval discontinue .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>severe acquire aplastic anemia</keyword>
	<keyword>SAA</keyword>
	<keyword>first line</keyword>
	<keyword>eltrombopag</keyword>
	<keyword>cyclosporine</keyword>
	<keyword>h-ATG</keyword>
	<keyword>severe aplastic anemia</keyword>
	<keyword>aplastic anemia</keyword>
</DOC>